Radiopharm Theranostics CEO Riccardo Canevari joined Steve Darling from Proactive to share news The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics has agreed to a joint venture to create novel radiopharmaceutical therapeutics for cancer. Canevari shared more about this collaboration and how it will work moving forward. Canevari also talk more about the company and also more recent news including the FDA granting a rare Pediatric Disease Designation for the company’s DUNP19 for Osteosarcoma.
Radiopharm Theranostics and U of Texas announce joint venture
